Kepler Cheuvreux Suisse SA Acquires New Stake in Cencora, Inc. $COR

Kepler Cheuvreux Suisse SA acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 81,233 shares of the company’s stock, valued at approximately $25,384,000. Cencora makes up 1.4% of Kepler Cheuvreux Suisse SA’s investment portfolio, making the stock its 25th biggest holding.

Other institutional investors have also recently added to or reduced their stakes in the company. IAG Wealth Partners LLC acquired a new stake in shares of Cencora during the 3rd quarter worth about $30,000. Cloud Capital Management LLC acquired a new position in shares of Cencora in the third quarter valued at approximately $31,000. Caitlin John LLC acquired a new position in shares of Cencora in the third quarter valued at approximately $31,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the period. Finally, Westside Investment Management Inc. lifted its stake in shares of Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock valued at $33,000 after buying an additional 70 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Wells Fargo & Company lifted their target price on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Evercore reduced their price target on Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Robert W. Baird set a $415.00 price objective on Cencora in a report on Tuesday, January 13th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Finally, Bank of America dropped their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $399.00.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,220 shares of company stock valued at $5,282,867 over the last 90 days. Corporate insiders own 0.38% of the company’s stock.

Cencora Stock Performance

Cencora stock opened at $351.97 on Wednesday. The company has a market cap of $68.47 billion, a price-to-earnings ratio of 42.30, a price-to-earnings-growth ratio of 1.69 and a beta of 0.68. Cencora, Inc. has a 12 month low of $251.94 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock’s 50-day moving average is $354.84 and its 200-day moving average is $337.51.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.73 EPS. Equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.